Rivaroxaban (Xarelto®), an oral direct factor Xa inhibitor, is approved for the initial treatment
of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of …

Patients with deep vein thrombosis or pulmonary embolism are recommended to receive
anticoagulation for acute treatment and secondary prevention of venous thromboembolism …

Over recent years, research on anticoagulant drugs has been guided by the requirement for
convenient administration and a wide therapeutic window to allow fixed dosing without the …

Anticoagulation therapy is the standard treatment of patients with symptomatic venous
thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Until …

Venous thromboembolism (VTE) is a major healthcare concern and affects more than 1.6
million individuals each year worldwide. Long-term complications include recurrent VTE …

Abstract Abstract 20 Harry R. Büller, MD, PhD on behalf of the EINSTEIN Investigators.
Background The EINSTEIN DVT and EINSTEIN PE studies showed that a fixed-dose …

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary
embolism, poses a substantial clinical risk, and the incidence of these thrombotic-related …

Abstract Objective: The phase III EINSTEIN DVT and EINSTEIN PE trials demonstrated the
potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary …

Background A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been
shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein …

Introduction Randomized clinical trials have demonstrated non-inferiority of rivaroxaban
compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism …